A novel cannabis intoxication testing device developed by Montana tech company Gaize, Inc. detected irregular eye movement in hundreds of subjects who consumed cannabis in a recent clinical trial.
On Friday, the company revealed it had tested the ocular intoxication measurement technology on 350 participants with “outstanding” results — according to the company’s Chief Technology Officer, Rob Lass. The VR headset assessment takes about six minutes to complete.
Testing methods used in the past for cannabis can detect THC in an individual’s system weeks after use but have been unable to determine whether they are currently under the influence.
The trial was completed in partnership with dicentra, a contract research organization (CRO) headquartered in Toronto. The CRO was responsible for facilitating successful data collection with the Gaize headset before and after cannabis use and ensuring that trial subjects were safe while under the influence.
Gaize plans to release the flagship product by the end of 2022 and is currently accepting reservations for it from law enforcement and businesses that have safety-critical operations.
“We have really put our cannabis impairment detection product through its paces. Based on the data we gathered, we have been able to capture important insights into how cannabis impairment manifests in eye movement,” said Rob Lass, Chief Technology Officer for Gaize.
“The impact this device could have on safety both on the road and in the workplace is for me, and everyone at dicentra, extremely exciting! We are very proud to have been a part of it and can’t wait to see the positive disruption this device brings globally,” added Peter Wojewnik, Partner at dicentra.